Alpha-2 adrenergic receptor

Alpha-2 adrenergic receptor
The alpha-2 (α2) adrenergic receptor (or adrenoceptor) is a G protein-coupled receptor (GPCR) associated with the Gi heterotrimeric G-protein. It consists of three highly homologous subtypes, including α2A-, α2B-, and α2C-adrenergic. Some species other than humans express a fourth α2D-adrenergic receptor as well. Catecholamines like norepinephrine (noradrenaline) and epinephrine (adrenaline) signal through the α2-adrenergic receptor in the central and peripheral nervous systems.
Cellular localization
The α2A adrenergic receptor is localised in the following central nervous system (CNS) structures:
Brainstem (especially the locus coeruleus as presynaptic & somatodendritic autoreceptor )
Midbrain
Hypothalamus
Olfactory system
Hippocampus
Spinal cord
Cerebral cortex
Cerebellum
Septum
Whereas the α2B adrenergic receptor is localised in the following CNS structures:
Thalamus
Pyramidal layer of the hippocampus
Cerebellar Purkinje layer
and the α2C adrenergic receptor is localised in the CNS structures:
Midbrain
Thalamus
Amygdala
Dorsal root ganglia
Olfactory system
Hippocampus
Cerebral cortex
Basal ganglia
Substantia nigra
Ventral tegmentum
Effects
The α2-adrenergic receptor is classically located on vascular prejunctional terminals where it inhibits the release of norepinephrine (noradrenaline) in a form of negative feedback. It is also located on the vascular smooth muscle cells of certain blood vessels, such as those found in skin arterioles or on veins, where it sits alongside the more plentiful α1-adrenergic receptor. The α2-adrenergic receptor binds both norepinephrine released by sympathetic postganglionic fibers and epinephrine (adrenaline) released by the adrenal medulla, binding norepinephrine with slightly higher affinity. It has several general functions in common with the α1-adrenergic receptor, but also has specific effects of its own. Agonists (activators) of the α2-adrenergic receptor are frequently used in anaesthesia where they affect sedation, muscle relaxation and analgesia through effects on the central nervous system (CNS).
In the brain, α2-adrenergic receptors can be localized either pre- or post-synaptically, and the majority of receptors appear to be post-synaptic. For example, the α2A adrenergic receptor subtype is post-synaptic in the prefrontal cortex and these receptors strengthen cognitive and executive functions by inhibiting cAMP opening of potassium channels, thus enhancing prefrontal connections and neuronal firing. The α2A-adrenergic agonist, guanfacine, is now used to treat prefrontal cortical cognitive disorders such as attention deficit hyperactivity disorder (ADHD).
General
Common effects include:
Suppression of release of norepinephrine (noradrenaline) by negative feedback
Transient hypertension (increase in blood pressure), followed by a sustained hypotension (decrease in blood pressure)
Vasoconstriction of certain arteries
Vasoconstriction of arteries to heart (coronary artery); however, the extent of this effect may be limited and may be negated by the vasodilatory effect from β2 receptors
Constriction of some vascular smooth muscle
Venoconstriction of veins
Decrease motility of smooth muscle in gastrointestinal tract
Inhibition of lipolysis
Facilitation of the cognitive functions associated with the prefrontal cortex (PFC; working memory, attention, executive functioning, etc.)
Sedation
Analgesia
Individual
Individual actions of the α2 receptor include:
Mediates synaptic transmission in pre- and postsynaptic nerve terminals
Decrease release of acetylcholine
Decrease release of norepinephrine
Inhibit norepinephrine system in brain
Inhibition of lipolysis in adipose tissue
Inhibition of insulin release in pancreas
Induction of glucagon release from pancreas
platelet aggregation
Contraction of sphincters of the gastrointestinal tract
Decreased secretion from salivary gland
Relax gastrointestinal tract (presynaptic effect)
Decreased aqueous humor fluid production from the ciliary body
Signaling cascade
The α subunit of an inhibitory G protein - Gi dissociates from the G protein, and associates with adenylyl cyclase. This causes the inactivation of adenylyl cyclase, resulting in a decrease of cAMP produced from ATP, which leads to a decrease of intracellular cAMP. PKA is not able to be activated by cAMP, so proteins such as phosphorylase kinase cannot be phosphorylated by PKA. In particular, phosphorylase kinase is responsible for the phosphorylation and activation of glycogen phosphorylase, an enzyme necessary for glycogen breakdown. Thus in this pathway, the downstream effect of adenylyl cyclase inactivation is decreased breakdown of glycogen.
The relaxation of gastrointestinal tract motility is by presynaptic inhibition, where transmitters inhibit further release by homotropic effects.
Agonists
4-NEMD
7-Me-marsanidine (also I1 agonist)
Agmatine (also I agonist, NMDA, 5-HT3, nicotinic antagonist and NOS inhibitor)
Apraclonidine
Brimonidine
Cannabigerol (also acts as a moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist).
Clonidine (also I1 agonist)
Detomidine
Dexmedetomidine
Fadolmidine
Guanabenz
Guanfacine
Lofexidine
Marsanidine
Medetomidine
Methyldopa
Mivazerol
Rilmenidine (also I agonist)
Romifidine
Talipexole (also dopamine agonist)
Tiamenidine
Tizanidine
Tolonidine
Xylazine
Xylometazoline
Partial agonists
Oxymetazoline (also α1 agonist)
TDIQ
Antagonists
1-PP (active metabolite of buspirone and gepirone)
Aripiprazole
Asenapine
Atipamezole
Cirazoline
Clozapine
Efaroxan
Idazoxan
Lurasidone
Melperone
Mianserin
Mirtazapine
Napitane
Olanzapine
Paliperidone (also primary active metabolite of risperidone)
Phenoxybenzamine
Phentolamine
Piribedil
Rauwolscine
Risperidone
Rotigotine (α2B antagonist, non-selective)
Quetiapine
Norquetiapine (primary active metabolite of quetiapine)
Setiptiline
Tolazoline
Yohimbine
Ziprasidone
Zotepine (discontinued)
Agonists
Norepinephrine has higher affinity for the α2 receptor than has epinephrine, and therefore relates less to the latter's functions. Nonselective α2 agonists include the antihypertensive drug clonidine, which can be used to lower blood pressure and to reduce hot flashes associated with menopause. Clonidine has also been successfully used in indications that exceed what would be expected from a simple blood-pressure lowering drug: it has recently shown positive results in children with ADHD who have tics resulting from the treatment with a CNS stimulant drug, such as Adderall XR or methylphenidate; clonidine also helps alleviate symptoms of opioid withdrawal. The hypotensive effect of clonidine was initially attributed through its agonist action on presynaptic α2 receptors, which act as a down-regulator on the amount of norepinephrine released in the synaptic cleft, an example of autoreceptor. However, it is now known that clonidine binds to imidazoline receptors with a much greater affinity than α2 receptors, which would account for its applications outside the field of hypertension alone. Imidazoline receptors occur in the nucleus tractus solitarii and also the centrolateral medulla. Clonidine is now thought to decrease blood pressure via this central mechanism. Other nonselective agonists include dexmedetomidine, lofexidine (another antihypertensive), TDIQ (partial agonist), tizanidine (in spasms, cramping) and xylazine. Xylazine has veterinary use.
In the European Union, dexmedetomidine received a marketing authorization from the European Medicines Agency (EMA) on August 10, 2012, under the brand name of Dexdor. It is indicated for sedation in the ICU for patients needing mechanical ventilation.
In non-human species this is an immobilizing and anesthetic drug, presumptively also mediated by α2 adrenergic receptors because it is reversed by yohimbine, an α2 antagonist.
α2A selective agonists include guanfacine (an antihypertensive) and brimonidine (UK 14,304).
(R)-3-nitrobiphenyline is an α2C selective agonist as well as being a weak antagonist at the α and α subtypes.
Antagonists
Nonselective α blockers include, A-80426, atipamezole, phenoxybenzamine, efaroxan, idazoxan (experimental), and SB-269,970.
Yohimbine is a relatively selective α2 blocker that has been investigated as a treatment for erectile dysfunction.
Tetracyclic antidepressants mirtazapine and mianserin are also potent α antagonists with mirtazapine being more selective for α2 subtype (~30-fold selective over α1) than mianserin (~17-fold).
α2A selective blockers include BRL-44408 and RX-821,002.
α2B selective blockers include ARC-239 and imiloxan.
α2C selective blockers include JP-1302 and spiroxatrine, the latter also being a serotonin 5-HT1A antagonist.
See also
Adrenergic receptor
References
External links
Adrenergic receptors
Human proteins